12:44 PM EST - Theralase Technologies Inc. : Has completed the Clinical Protocol and Investigator’s Brochure detailing the application of its lead light activated Photo Dynamic Compound, TLD-1433 in the treatment of Non-Muscle Invasive Bladder Cancer. Theralase Technologies Inc.
shares V.TLT are trading up $0.01 at $0.31.
